Bph Global Ltd

BP8

BPH Global Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company is headquartered in Melbourne, New South Wales. The company went IPO on 2000-06-13. The firm is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. The company focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. The firm produces its products through various plants, which include Caulerpa lentillifera, Dendrobium officinale, Resina and Cannabis sativa. The company is also into the sales and distribution of bird's nest products in China. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, and SCU Southeast Asia Sdn Bhd, SCU (HK) Ltd.

Bank of Queensland Limited

BOQPG

Bank of Queensland Ltd. engages in the provision of financial services to the community. The company is headquartered in Brisbane, Queensland and currently employs 3,248 full-time employees. The Company’s operating segments include Retail Banking and BOQ Business. The Retail Banking segment provides retail banking solutions to customers through its owner-managed and corporate branch network, third-party intermediaries, and virgin money distribution channels. Its Owner-Managed Branches retail and small and medium enterprises (SME) lending, deposits, credit cards and insurance. Its VMA business include digital home loans, deposits, credit cards, insurance, and superannuation. The BOQ Business segment includes the BOQ branded commercial lending activity, BOQ Finance and BOQ Specialist businesses. The company also provides tailored business banking solutions, including commercial lending, equipment finance and leasing, cashflow finance, foreign exchange, interest rate hedging, transaction banking and deposit solutions for commercial customers. The company operates more than 160 branches across Australia.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.